NeurogesX publish Phase III data on NGX-4010 in HIV neuropathy « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

NeurogesX publish Phase III data on NGX-4010 in HIV neuropathy

Posted on June 10, 2008 by crimsoncanary

NeurogesX have published Phase 3 data of its lead capsaicin product NGX-4010 in Neurology. The trial, in patients with HIV-associated distal sensory polyneuropathy (HIV-DSP) showed the drug to statistically reduce pain over a 12-week period.

Filed under: Uncategorized | Tagged: agonist, NeurogesX, NGX-4010, NGX4010, phase III, TRPV1, Vanilloid, VR1

« OSI present data on dual 5-HT1A agonist/Monoamine reuptake inhibitor Targacept and AstraZeneca Initiate Phase II Trial of Neuronal Nicotinic agonist AZD3480 »

Leave a Reply